I didn't even see the response. With ARNA there are actually three plays, VVUS, ARNA and OREX. They're all vying for the market that Phen fen once had, an estimated $10+ billion market. VVUS has the first FDA panel next week, I wish I had explained all this earlier because I marked it as a definite buy, but I'm not buying. I started seeing activity at the $9.6 range for VVUS and now its at $11 with another 7 days before decision. Play the run up, DO NOT hold on July 16th, its just too risky.

From what I'm seeing as goes VVUS, so goes ARNA and OREX. VVUS has the highest share price right now with the biggest run up, their weight loss product Qnexa had the most drastic weight loss but safety is a slight issue with them. ARNA has the lowest share price of them all, weight loss for their product was substancial but not stellar, but it was the safest drug of them all. OREX, safety issues and the results fell between ARNA and VVUS. If I was going to play run ups only, buy VVUS right now and sell on the 15th. Afer then buy ARNA, their panel is not until September with an FDA decision in October, hold till early October before the FDA date and sell. Buy OREX, they're not scheduled for review until December but their run up will be meager if both ARNA and VVUS are approved.

The way I'm playing it is strictly long on ARNA, and I am all in. ARNA will have a run up with the VVUS panel, the price may retreat after than and continue upward going into September and October. I am selling before the FDA date, ARNA will get approved but there will be a fall back, for the time being my funds will go into AVNR until late October, wait for ARNA to retrace and buy back in before ARNA's product hits the street. I expect the FDA run up to go around $8-$10. Retrace maybe to $5 or $6 after approval.. but long term ARNA is easily priced in the $20-$25 range.

Fundamentals. 100 million share float, just partnered a $1.3 Billion deal but it is loaded on the back end. Sales have to be reported before they see much of that money. Deals in Europe and Asia have yet to come. This is not a penny stock and this is not an overnight millionaire deal, what it is, is a play with sound fundamentals, risk is there but it is relatively minimal. I'd say medium risk, high reward with a good amount of patience.